Özet PDF Benzer Makaleler Yazara Mail Gönder

¹Hacettepe Üniversitesi, Kanser Enstitüsü Medikal Onkoloji Bilim Dalı, Ankara, Türkiye Gliomas are tumors originating from brain parenchymal cells and are the most common primary neoplasms of the central nervous system. These tumors cause high morbidity and mortality. Surgical approach is the backbone of treatment and the effect of multimodal approaches on survival has been shown. In addition, systemic treatment is the treatment of choice in patients with unresectable or recurrent disease. The efficacy of temozolamide, nitrosourea and bevacizumab has been demonstrated at various stages. The importance of mooecular pathology in the choice of treatment and predicting prognosis is increasing gradually. MGMT promoter methylation in anaplastic astrocytoma and glioblastoma and 1p/19 codification in oligodendrogliomas are good prognostic groups with high chemotherapy efficacy. Immunotherapies are being investigated for both adjuvant and recurrent diseases in this group, where the unmet need is high. It is hoped that the outcome of ongoing immunotherapy studies will lead to a paradigm shift. Anahtar Kelimeler : Glioma, Temozolamide, Chemoradiotherapy, Immunotherapy, Mgmt, Glioblastoma, Oligodendroglioma